{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:05:16Z","timestamp":1751515516806,"version":"3.41.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T00:00:00Z","timestamp":1520208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00108-018-0397-2","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T09:13:32Z","timestamp":1520241212000},"page":"341-351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Medikament\u00f6se Therapie der rheumatoiden Arthritis und ihrer Komorbidit\u00e4ten","Pharmacological treatment of rheumatoid arthritis and its comorbidities"],"prefix":"10.1007","volume":"59","author":[{"given":"K.","family":"Kr\u00fcger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,5]]},"reference":[{"key":"397_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00393-013-1258-y","volume":"73","author":"A Zink","year":"2014","unstructured":"Zink A (2014) Versorgungsforschung in der Rheumatologie \u2013 aktueller Stand. Z\u00a0Rheumatol 73:115\u2013122","journal-title":"Z Rheumatol"},{"key":"397_CR2","volume-title":"Kerndokumentation 2015","author":"Deutsches Rheumaforschungszentrum Berlin","year":"2015","unstructured":"Deutsches Rheumaforschungszentrum Berlin (2015) Kerndokumentation 2015. www.drfz.de . Zugegriffen: 2.1.2018"},{"key":"397_CR3","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977","journal-title":"Ann Rheum Dis"},{"key":"397_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR et\u00a0al (2016) Treating\u00a0rheumatoid arthritis to\u00a0target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3\u201315","journal-title":"Ann Rheum Dis"},{"key":"397_CR5","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s00393-012-1038-0","volume":"71","author":"K Kr\u00fcger","year":"2012","unstructured":"Kr\u00fcger K, Wollenhaupt J, Albrecht K et al (2012) S1-Leitlinie der DGRh zur sequenziellen medikament\u00f6sen Therapie der rheumatoiden Arthritis 2012. Z\u00a0Rheumatol 71:592\u2013603","journal-title":"Z Rheumatol"},{"key":"397_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/annrheumdis-2016-209212","volume":"76","author":"P Verschueren","year":"2017","unstructured":"Verschueren P, de Cock D, Corluy L et al (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a\u00a0treat-to-target approach: 1\u2011year results of\u00a0CareRA, a\u00a0randomised pragmatic open-label superiority trial. Ann Rheum Dis 76:511\u2013520","journal-title":"Ann Rheum Dis"},{"key":"397_CR7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.20452\/pamw.1131","volume":"122","author":"D Golicki","year":"2012","unstructured":"Golicki D, Niewada M, Lis J et al (2012) Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials. Pol Arch Med Wewn 122:22\u201332","journal-title":"Pol. Arch. Med. Wewn."},{"key":"397_CR8","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl C, Bijlsma JWJ, de Wit M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 75:952\u2013957","journal-title":"Ann Rheum Dis"},{"key":"397_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D et\u00a0al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N\u00a0Engl J Med 376:652\u2013662","journal-title":"N Engl J Med"},{"key":"397_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211937","author":"J Kay","year":"2017","unstructured":"Kay J, Schoels MM, D\u00f6rner T et al (2017) Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211937","journal-title":"Ann Rheum Dis"},{"key":"397_CR11","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay C, Emery P, van Vollenhoven R et al (2013) Tocilizumab\u00a0monotherapy versus\u00a0adalimumab\u00a0monotherapy for treatment of rheumatoid arthritis (ADACTA): a\u00a0randomised, double-blind, controlled phase 4 trial. Lancet 381:1541\u20131550","journal-title":"Lancet"},{"key":"397_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Lin Y, Patel R et al (2017) Efficacy and safety of\u00a0sarilumab\u00a0monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a\u00a0randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 76:840\u2013847","journal-title":"Ann Rheum Dis"},{"key":"397_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheum 69:506\u2013517","journal-title":"Arthritis Rheum"},{"key":"397_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a\u00a0phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:457\u2013468","journal-title":"Lancet"},{"key":"397_CR15","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/ard.2011.151043","volume":"70","author":"A Strangfeld","year":"2011","unstructured":"Strangfeld A, Eveslage M, Schneider M et al (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70:1914\u20131920","journal-title":"Ann Rheum Dis"},{"key":"397_CR16","unstructured":"Deutsche Gesellschaft f\u00fcr Rheumatologie www.dgrh.de - Therapie\u00fcberwachung. Zugegriffen: 2.1.2018"},{"key":"397_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/acr.22642","volume":"68","author":"BR England","year":"2016","unstructured":"England BR, Sayles H, Michaud K et al (2016) Cause-specific mortality in male US veterans with\u00a0rheumatoid arthritis. Arthritis Care Res 68:36\u201345","journal-title":"Arthritis Care Res"},{"key":"397_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00393-016-0064-8","volume":"75","author":"K Kr\u00fcger","year":"2016","unstructured":"Kr\u00fcger K (2016) Therapie kardiovaskul\u00e4rer Risikofaktoren. Z\u00a0Rheumatol 75:173\u2013180","journal-title":"Z Rheumatol"},{"key":"397_CR19","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH et al (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a\u00a0chimeric monoclonal antibody to tumor necrosis factor- a, in patients with moderate-to-severe heart failure : results of the anti-TNF therapy against congestive heart failure. ATTACH trial. Circulation 107:3133\u20133140","journal-title":"Circulation"},{"key":"397_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","volume":"77","author":"C Rempenault","year":"2018","unstructured":"Rempenault C, Combe B, Barnetche T et al (2018) Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a\u00a0systematic review and meta-analysis. Ann Rheum Dis 77:98\u2013103","journal-title":"Ann Rheum Dis"},{"key":"397_CR21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Coxib and traditional NSAID Trialists\u2019 (CNT) Collaboration, Bhala N, Emberson J, Merhi A et al (2013) Vascular and upper gastrointestinal effects of non-steroidal antiinflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:769\u2013779","journal-title":"Lancet"},{"key":"397_CR22","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1055\/s-0043-112255","volume":"142","author":"K Kr\u00fcger","year":"2017","unstructured":"Kr\u00fcger K (2017) Nichtsteroidale Antirheumatika bei rheumatischen Erkrankungen \u2013 was spricht daf\u00fcr? Dtsch Med Wochenschr 142:1773\u20131774","journal-title":"Dtsch Med Wochenschr"},{"key":"397_CR23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richter V, Starnino T et al (2015) The effects of tumournecrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a\u00a0systematic review and meta-analysis. Ann Rheum Dis 74:480\u2013489","journal-title":"Ann Rheum Dis"},{"key":"397_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/BOR.0000000000000380","volume":"29","author":"C Johnson","year":"2017","unstructured":"Johnson C (2017) Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol 29:254\u2013259","journal-title":"Curr Opin Rheumatol"},{"key":"397_CR25","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","volume":"76","author":"C Hyldgaard","year":"2017","unstructured":"Hyldgaard C, Hilberg O, Pedersen AB et al (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76:1700\u20131706","journal-title":"Ann Rheum Dis"},{"key":"397_CR26","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s10067-017-3707-5","volume":"36","author":"J Rojas-Serrano","year":"2017","unstructured":"Rojas-Serrano J, Herrera-Bringas D, Perez-Roman DI et al (2017) Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol 36:1493\u20131500","journal-title":"Clin Rheumatol"},{"key":"397_CR27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2165\/11316650-000000000-00000","volume":"32","author":"N Alcom","year":"2009","unstructured":"Alcom N, Saunder S, Madhok R (2009) Benefit-risk assessment of\u00a0leflunomide: an appraisal of\u00a0leflunomide\u00a0in rheumatoid arthritis 10 years after licensing. Drug Saf 32:1123\u20131134","journal-title":"Drug Saf"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0397-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0397-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0397-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T10:02:07Z","timestamp":1751450527000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0397-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,5]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["397"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0397-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"type":"print","value":"0020-9554"},{"type":"electronic","value":"1432-1289"}],"subject":[],"published":{"date-parts":[[2018,3,5]]},"assertion":[{"value":"5 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Kr\u00fcger hat f\u00fcr Beratung und Vortr\u00e4ge Honorare von den Firmen AbbVie, Biogen, BMS, Hexal, Lilly, Medac, MSD, Novartis, Pfizer, Roche, Sanofi und UCB erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine vom Autor durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}